E. YAO ET AL: "Suppression of HER2/HER3-Mediated Growth of Breast Cancer Cells with Combinations of GDC-0941 PI3K Inhibitor, Trastuzumab, and Pertuzumab", CLINICAL CANCER RESEARCH, vol. 15, no. 12, 9 June 2009 (2009-06-09), pages 4147-4156, XP055101738, ISSN: 1078-0432, DOI: 10.1158/1078-0432.CCR-08-2814 (B1)

HSIEH A C ET AL: "Targeting HER proteins in cancer therapy and the role of the non-target HER3", BRITISH JOURNAL OF CANCER, NATURE PUBLISHING GROUP, LONDON, GB, vol. 97, no. 4, 1 August 2007 (2007-08-01) , pages 453-457, XP009123247, ISSN: 0007-0920 (B1)

Merrimack Pharmaceuticals: "A study of MM-121 combination therapy in patients with advanced non-small cell lung cancer", ClinicalTrials.gov , 13 October 2009 (2009-10-13), XP002726209, Retrieved from the Internet: URL:http://www.clinicaltrials.gov/ct2/show /record/NCT00994123?term=MM-121&rank=1 [retrieved on 2014-06-25] -& "View of NCT00994123 on 2009_10_13", ClinicalTrials.gov archive , 13 October 2009 (2009-10-13), XP002726210, Retrieved from the Internet: URL:http://clinicaltrials.gov/archive/NCT0 0994123/2009_10_13 [retrieved on 2014-06-25] (B1)

WO-A2-2008/100624 (B1)

WO-A1-00/78347 (B1)

WO-A2-2007/013950 (B1)

WO-A2-2007/077028 (B1)

TREDER M ET AL: "309 POSTER Fully human anti-HER3 mAb U3-1287 (AMG 888) demonstrates unique in vitro and in vivo activities versus other HER family inhibitors in NSCLC models", EUROPEAN JOURNAL OF CANCER. SUPPLEMENT, PERGAMON, OXFORD, GB, vol. 6, no. 12, 1 October 2008 (2008-10-01), page 99, XP025534373, ISSN: 1359-6349, DOI: DOI:10.1016/S1359-6349(08)72243-2 [retrieved on 2008-10-01] (B1)